The 1st conference of the ARCA Global network aims to advance a global consortium for translational studies in autosomal-recessive ataxias (ARCAs), ARCA Global. ARCA Global is a dynamic, collaborative translational research initiative ultimately aiming to prepare and conduct harmonized multi-center treatment trials in genetically stratified ARCAs, thus allowing to translate the recent progress in ARCA genetics directly into stringent targeted treatment trials. It will integrate all main stakeholder groups including basic and clinician scientists, industry, and patient organizations.
WTS2020 is the largest business and prosumer show featuring cutting edge technology under one roof. It is the biggest and best forum for forming partnerships and developing new business across the wearable, smart device and IOT landscape. Boasting 8 conference tracks; in conjunction with the AVR360 Show, and Digital Healthcare Show, WTS2020 offers an unrivalled breadth and depth of content.
The AAT-AD/PD™ Focus Meeting 2020 will present all the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological disorders.
A central theme will be to further advance innovative strategies in therapy and prevention, clinical trials and diagnostic markers discussed in the sessions and corridors at AD/PD™ 2019, in order to focus on driving successful collaborations among academia and industry, leading to the development of innovative therapies and ultimately providing for a better future for patients and families affected by neurodegenerative diseases.
The spinocerebellar ataxias (SCAs) are a group of autosomal dominantly inherited progressive ataxia disorders. SCA Global is a worldwide initiative for clinical research in SCAs and provides a flexible and open research platform to pursue the following goals: 1. To better understand the manifestation, evolution and impact of the various SCAs, 2. To develop and validate biomarkers which can be used in future interventional trials, 3. To facilitate access to people with SCAs who are willing to participate in clinical trials.